MA31072B1 - Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes - Google Patents

Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes

Info

Publication number
MA31072B1
MA31072B1 MA32013A MA32013A MA31072B1 MA 31072 B1 MA31072 B1 MA 31072B1 MA 32013 A MA32013 A MA 32013A MA 32013 A MA32013 A MA 32013A MA 31072 B1 MA31072 B1 MA 31072B1
Authority
MA
Morocco
Prior art keywords
formula
tetrahydrocyclopenta
modulators
compound
androgen receptor
Prior art date
Application number
MA32013A
Other languages
English (en)
French (fr)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Prabhakar Kondaji Jadhav
Donald Paul Matthews
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31072B1 publication Critical patent/MA31072B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MA32013A 2006-11-20 2009-06-17 Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes MA31072B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
MA31072B1 true MA31072B1 (fr) 2010-01-04

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32013A MA31072B1 (fr) 2006-11-20 2009-06-17 Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes

Country Status (36)

Country Link
US (1) US7968587B2 (OSRAM)
EP (1) EP2094658B1 (OSRAM)
JP (1) JP5399259B2 (OSRAM)
KR (1) KR101121471B1 (OSRAM)
CN (1) CN101541749B (OSRAM)
AR (1) AR063559A1 (OSRAM)
AT (1) ATE538091T1 (OSRAM)
AU (1) AU2007324046B2 (OSRAM)
BR (1) BRPI0719092B8 (OSRAM)
CA (1) CA2670340C (OSRAM)
CL (1) CL2007003182A1 (OSRAM)
CO (1) CO6190513A2 (OSRAM)
CR (1) CR10802A (OSRAM)
CY (1) CY1112284T1 (OSRAM)
DK (1) DK2094658T3 (OSRAM)
EA (1) EA015627B1 (OSRAM)
EC (1) ECSP099350A (OSRAM)
ES (1) ES2376048T3 (OSRAM)
HR (1) HRP20120032T1 (OSRAM)
IL (1) IL198410A (OSRAM)
JO (1) JO2800B1 (OSRAM)
MA (1) MA31072B1 (OSRAM)
MX (1) MX2009005251A (OSRAM)
MY (1) MY154547A (OSRAM)
NO (1) NO342531B1 (OSRAM)
NZ (1) NZ576296A (OSRAM)
PE (1) PE20081161A1 (OSRAM)
PL (1) PL2094658T3 (OSRAM)
PT (1) PT2094658E (OSRAM)
RS (1) RS52191B (OSRAM)
SI (1) SI2094658T1 (OSRAM)
TN (1) TN2009000189A1 (OSRAM)
TW (1) TWI398438B (OSRAM)
UA (1) UA98777C2 (OSRAM)
WO (1) WO2008063867A2 (OSRAM)
ZA (1) ZA200903096B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
BRPI0912394A2 (pt) * 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
BR112013007685B1 (pt) 2010-09-28 2021-11-09 Radius Pharmaceuticals, Inc Compostos moduladores de receptor andrógeno seletivos, composição farmacêutica compreendendo os referidos compostos, método de identificação de um composto capaz de modular um receptor andrógeno, usos de um composto ou da composição e processo para a preparação de um composto
EP2707373A1 (de) 2011-05-10 2014-03-19 Bayer Intellectual Property GmbH Bicyclische (thio)carbonylamidine
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
JP7221699B2 (ja) 2016-06-22 2023-02-14 エリプセス ファーマ エルティーディー Ar+乳癌の治療方法
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
KR20210127961A (ko) 2019-02-12 2021-10-25 래디어스 파마슈티컬스, 인코포레이티드 방법 및 화합물
US20230096602A1 (en) * 2020-01-27 2023-03-30 Eirgen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for treatment of renal disease
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
KR100731566B1 (ko) * 1999-10-14 2007-06-22 가켄 세야쿠 가부시키가이샤 테트라히드로퀴놀린 유도체
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしてのシクロヘプタBインドール誘導体
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
ES2414604T3 (es) * 2004-03-03 2013-07-22 Eli Lilly And Company Moduladores del receptor nuclear de hormonas esteroides de derivados bicíclicos sustituidos con indol
EP1817026A2 (en) * 2004-11-22 2007-08-15 SmithKline Beecham Corporation Hcv inhibitors
US8946444B2 (en) 2004-11-23 2015-02-03 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control
AR052674A1 (es) 2005-02-17 2007-03-28 Wyeth Corp Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
MX2007015905A (es) 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
BRPI0912394A2 (pt) 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol

Also Published As

Publication number Publication date
NZ576296A (en) 2011-11-25
MX2009005251A (es) 2009-08-19
BRPI0719092B1 (pt) 2020-08-18
EA200970500A1 (ru) 2009-10-30
PL2094658T3 (pl) 2012-05-31
SI2094658T1 (sl) 2012-04-30
JO2800B1 (en) 2014-03-15
TN2009000189A1 (en) 2010-10-18
EA015627B1 (ru) 2011-10-31
CR10802A (es) 2009-07-13
CN101541749A (zh) 2009-09-23
ES2376048T3 (es) 2012-03-08
WO2008063867A2 (en) 2008-05-29
IL198410A (en) 2013-09-30
BRPI0719092B8 (pt) 2021-05-25
PT2094658E (pt) 2012-02-22
BRPI0719092A2 (pt) 2013-12-03
HK1134089A1 (en) 2010-04-16
AR063559A1 (es) 2009-02-04
PE20081161A1 (es) 2008-08-15
ECSP099350A (es) 2009-06-30
AU2007324046B2 (en) 2012-04-05
UA98777C2 (en) 2012-06-25
EP2094658B1 (en) 2011-12-21
JP5399259B2 (ja) 2014-01-29
HRP20120032T1 (hr) 2012-02-29
KR101121471B1 (ko) 2012-02-28
CY1112284T1 (el) 2015-12-09
DK2094658T3 (da) 2012-02-13
CA2670340A1 (en) 2008-05-29
MY154547A (en) 2015-06-30
TWI398438B (zh) 2013-06-11
TW200827347A (en) 2008-07-01
RS52191B (sr) 2012-10-31
NO342531B1 (no) 2018-06-11
CO6190513A2 (es) 2010-08-19
CN101541749B (zh) 2013-03-27
ATE538091T1 (de) 2012-01-15
EP2094658A2 (en) 2009-09-02
WO2008063867A3 (en) 2008-07-31
CL2007003182A1 (es) 2008-06-27
IL198410A0 (en) 2010-02-17
US20100069404A1 (en) 2010-03-18
NO20092103L (no) 2009-05-28
KR20090082229A (ko) 2009-07-29
ZA200903096B (en) 2010-07-28
US7968587B2 (en) 2011-06-28
AU2007324046A1 (en) 2008-05-29
JP2010510231A (ja) 2010-04-02
CA2670340C (en) 2014-05-20

Similar Documents

Publication Publication Date Title
MA31072B1 (fr) Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes
WO2009140448A8 (en) Tetrahydrocyclopenta[b]indole androgen receptor modulators
WO2006124447A3 (en) Substituted n-arylpyrrolidines as selective androgen receptor modulators
WO2007002181A3 (en) Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
MA29791B1 (fr) Composes therapeutiques.
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA30672B1 (fr) Utilisation de derives de l'azabicyclo hexane
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
MA30807B1 (fr) Compositions pharmaceutiques.
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA30604B1 (fr) Agonistes de ep2
CA2360313A1 (en) Glucocorticoid receptor modulators
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
CA2360308A1 (en) Glucocorticoid receptor modulators
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
WO2006070325A3 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
RU2008119410A (ru) Диспергируемые таблетки, включающие деферасирокс
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
MX2007011280A (es) Dipirazoles como farmacos del sistema nervioso central.
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
MX2010007967A (es) N-[3-bromo-2-cloro-4-(4,5-dihidro-1h-imidazol-2-ilmetil)-fenil]-m etansulfoamida como agonista parcial alfa-1 a adrenergico para el tratamiento de la incontinencia.